


I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office on March 18, 2008.

  
Frank C. Eisenschen, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

Patent Application  
Docket No. ARS-120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1644  
Applicant : Yolande Chvatchko  
Serial No. : 10/565,741  
Filed : January 23, 2006  
Conf. No. : 2192  
For : Use of Soluble CD164 in Inflammatory and/or Autoimmune Disorders

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. The fee of \$180.00 was paid at the time this Information Disclosure Statement was filed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/ks

Attachments: Form PTO/SB/08; copies of references cited therein.